-
公开(公告)号：US12071425B2
公开(公告)日：2024-08-27
申请号：US17275606
申请日：2019-09-12
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Cuong Q. Ly , Georgette Castanedo , Paul Gibbons , Wendy Lee , Joachim Rudolph , Nicole Alice Blaquiere , Jacob Bradley Schwarz , Ramsay Beveridge , Jean-Philippe Leclerc , Alexandre Lemire , Leo Fu
IPC: C07D401/14 , A61K45/06 , C07D401/04 , C07D413/14 , C07D471/04 , C07D471/08
CPC classification number: C07D401/14 , A61K45/06 , C07D401/04 , C07D413/14 , C07D471/04 , C07D471/08
Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
公开(公告)号：US11993599B2
公开(公告)日：2024-05-28
申请号：US17883004
申请日：2022-08-08
Applicant: Genentech, Inc.
Inventor： Elisia Villemure , Joachim Rudolph , Mingshuo Zeng
IPC: C07D471/14 , A61K31/501 , C07D471/08 , C07D471/10 , C07D487/14
CPC classification number: C07D471/08 , C07D471/10 , C07D487/14
Abstract: The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.
-
公开(公告)号：US10968203B2
公开(公告)日：2021-04-06
申请号：US15989008
申请日：2018-05-24
Inventor： Marie-Gabrielle Braun , Paul Gibbons , Wendy Lee , Cuong Ly , Joachim Rudolph , Jacob Schwarz , Avi Ashkenazi , Leo Fu , Tommy Lai , Fei Wang , Ramsay Beveridge , Liang Zhao
IPC: A61K31/506 , A61K45/06 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , A61P35/00
Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I′ structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I′ compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
4.发明申请公开(公告)号：US20180265497A1
公开(公告)日：2018-09-20
申请号：US15989008
申请日：2018-05-24
Inventor： Marie-Gabrielle Braun , Paul Gibbons , Wendy Lee , Cuong Ly , Joachim Rudolph , Jacob Schwarz , Avi Ashkenazi , Leo Fu , Tommy Lai , Fei Wang , Ramsay Beveridge , Liang Zhao
IPC: C07D401/14 , A61K31/506 , C07D401/04 , C07D405/14 , C07D417/14 , C07D413/14 , A61K45/06
CPC classification number: C07D401/14 , A61K31/506 , A61K45/06 , A61P35/00 , C07D401/04 , C07D405/14 , C07D413/14 , C07D417/14
Abstract: Described herein are pyrimidinyl-pyridyloxy-naphthyl compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I or I′ structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I or I′ compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
公开(公告)号：US20150031674A1
公开(公告)日：2015-01-29
申请号：US14340792
申请日：2014-07-25
Applicant: GENENTECH, INC.
Inventor： Joachim Rudolph , Lewis J. Gazzard , James J. Crawford , Chudi Ndubaku , Joy Drobnick , Wendy Lee
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: Compounds having the formula I wherein R1, R2, R3, R4, R5, Ra, Rb, Rc, Rd, Re, n, r, s and t are as defined herein and which compounds are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
Abstract translation: 具有式I的化合物，其中R1，R2，R3，R4，R5，Ra，Rb，Rc，Rd，Re，n，r，s和t如本文所定义，哪些化合物是PAK1的抑制剂。 还公开了用于治疗癌症和过度增殖性疾病的组合物和方法。
-
Patent Agency Ranking
公开(公告)号：US20230057166A1
公开(公告)日：2023-02-23
申请号：US17275606
申请日：2019-09-12
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Cuong Q. Ly , Georgette Castanedo , Paul Gibbons , Wendy Lee , Joachim Rudolph , Nicole Alice Blaquiere , Jacob Bradley Schwarz , Ramsay Beveridge , Jean-Philippe Leclerc , Alexandre Lemire , Leo Fu
IPC: C07D401/14 , C07D401/04 , C07D413/14 , C07D471/04 , C07D471/08 , A61K45/06
Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
-
公开(公告)号：US20230047209A1
公开(公告)日：2023-02-16
申请号：US17366923
申请日：2021-07-02
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Georgette Castanedo , Paul Gibbons , Joachim Rudolph , William Vernier , Ramsay Beveridge , Yao Wu , Guosheng Wu
IPC: C07D471/04 , C07D475/00
Abstract: Described herein are pyrido-pyrimidinone and pteridinone compounds or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods treating cancer, alone and in combination with other therapeutic agents.
-
公开(公告)号：US20220249487A1
公开(公告)日：2022-08-11
申请号：US17643623
申请日：2021-12-10
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Georgette Castanedo , Paul Gibbons , Joachim Rudolph , Yao Wu , Guosheng Wu
IPC: A61K31/517 , C07D401/12 , C07D239/84 , C07D401/04 , C07D401/14 , A61K31/573 , A61K38/07 , A61K31/69 , A61K31/454 , A61K39/395 , C07D405/14
Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof useful in the treatment of IRE1-related diseases and disorders described herein.
-
公开(公告)号：US08815877B2
公开(公告)日：2014-08-26
申请号：US13723770
申请日：2012-12-21
Applicant: Genentech, Inc.
Inventor： Ignacio Aliagas-Martin , James Crawford , Wendy Lee , Simon Mathieu , Joachim Rudolph
IPC: C07D403/12 , A61K31/505
CPC classification number: A61K31/519 , A61K31/506 , A61K45/06 , C07D471/04 , C07D487/04
Abstract: Compounds having the formula I wherein A, R1a, R1b, R2, R3, R4, R5, R6, R7, R8, Ra, Rb, X1, X2, X3 and n are as defined herein are inhibitors of PAK1. Also disclosed are compositions and methods for treating cancer and hyperproliferative disorders.
Abstract translation: 具有式I的化合物，其中A，R1a，R1b，R2，R3，R4，R5，R6，R7，R8，Ra，Rb，X1，X2，X3和n如本文所定义是PAK1的抑制剂。 还公开了用于治疗癌症和过度增殖性疾病的组合物和方法。
-
公开(公告)号：US20220204498A1
公开(公告)日：2022-06-30
申请号：US17404568
申请日：2021-08-17
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Joachim Rudolph , Yao Wu , Guosheng Wu
IPC: C07D471/04
Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof useful in the treatment of IRE1-related diseases and disorders described herein.
-
-
-
-
-
-
-
-
-
Search Results
11
records
(took 0.031 seconds)
